SCITECH DEVELOPMENT

Advancing Cancer Treatment Through Safer Drug Delivery

A MESSAGE FROM OUR CEO

We're at a pivotal time in the company—and I couldn't be more energized by the momentum we've built. Whether you've been with us from the beginning or are just getting to know SciTech, I want to personally thank you for your interest and support.

Our oncology drug trial, utilizing ST-001 nanoFenretinide™, is performing exceptionally well, as you will see in this newsletter. In our ongoing Phase 1a/b trial for T-cell non-Hodgkin lymphoma, we're seeing what we were expecting: strong safety and drug tolerability, early signs of efficacy, and most importantly, patients telling us they just feel better.

We've also reached several key inflection points that position us for scalable growth:

✅ Raised $16+ Million in capital
✅ 100% increase in drug manufacturing
✅ Targeting FDA filings in 12-18 months
✅ Second FDA approval to launch a Phase 1a/b trial in Small Cell Lung Cancer

We're seeing growing engagement from new investors, top-tier venture firms, biopharma collaborators, and leading oncology experts who recognize the unique potential of ST-001 nanoFenretinide and the broader value of our platform.

Stay with us - the story ahead is one you won't want to miss.

With much appreciation,

Earle Holsapple
Chief Executive Officer
SciTech Development, Inc.

BREAKING NEWS!

Pivotal Data and Breakthrough Results Signal Major Advances in Our Trial Progress

The latest data from our ongoing Phase 1a Standard trial has exceeded our initial expectations as we enter therapeutic dosing levels.

At Dose Level 11 (of 13 doses), all five patients in the ongoing cohort have shown encouraging clinical activity—three with partial responses (two confirmed) and two with stable disease. Notably, all patients in this cohort are experiencing lesion shrinkage without new tumors and symptom relief.

These remarkable early results strengthen our conviction that ST-001 nanoFenretinide will revolutionize cancer treatment and deliver transformative outcomes for patients.
Read the Press Release

IN THIS NEWSLETTER

- **CLINICAL UPDATES**
  - T-cell NHL Trial - Early Success
  - Advancing Into Small Cell Lung Cancer
  - Featuring Dr. Akilov (Principal Investigator)
- **FUNDING AND SERIES A LAUNCH**
  - Featuring Investor Brad Daniels
- **FINANCIAL MILESTONES**
- **SPOTLIGHT ON JOHN CHAPMAN, CPA:**
  - Senior Financial Advisor
- **MANUFACTURING: SCALING UP**
- **STRENGTHENING OUR IP AND COMPETITIVE EDGE**
- **NEWS AND EVENTS**
- **LOOKING AHEAD**

CLINICAL UPDATES



T-CELL NHL TRIAL UPDATE:

SCITECH DEVELOPMENT CONTINUES TO ADVANCE ITS CLINICAL PROGRAMS WITH EARLY SUCCESS

We have completed our Phase 1a Accelerated trial and achieved the initial goal of confirming the safe delivery of fenretinide, supported by strong preliminary safety data. Notably, in Doses 1–9, we observed two partial responses and several cases of stable disease.

By utilizing the FDA-approved Phase 1a Accelerated design, SciTech was able to implement a faster dose-escalation strategy that helps to identify safe and potentially effective doses more quickly and enables faster clinical trial decision-making.

We are now dosing patients in the Phase 1a Standard portion of the trial, which follows a more traditional stepwise dose-escalation approach. In this phase, each dose is evaluated in cohorts of three patients, compared to the single-patient dose escalation used in the Accelerated phase, as drug safety evaluation continues.

So far, we're seeing further compelling data: increases in both disease stabilization and partial responses.

These exciting findings further strengthen the impressive safety and efficacy profile of ST-001 nanoFenretinide.
Patient enrollment is ongoing.

To learn more about the trial, eligibility, and 9 participating sites, please visit:

https://clinicaltrials.gov/study/NCT04234048

"It has been a pleasure working with the SciTech team as the lead investigator on the ST-001 nanoFenretinide study. The company's professionalism, scientific rigor, and responsiveness have made for a highly collaborative and productive experience. I am particularly excited about the potential of fenretinide phospholipid suspension as a novel therapeutic option for patients with cutaneous T-cell lymphoma, and I look forward to seeing how it continues to advance in clinical development."

Oleg E. Akilov, MD, PhD, is the Assistant Professor of the Department of Dermatology at the University of Pittsburgh and Director of the Cutaneous Lymphoma Program. He serves as the Principal Investigator for the T-cell NHL clinical trial.



ADVANCING INTO SMALL CELL LUNG CANCER

In more exciting news, the FDA has cleared our Investigational New Drug application (IND) to begin a clinical trial in Small Cell Lung Cancer (SCLC), a notoriously aggressive cancer with limited treatment options.
The University of Michigan will serve as the lead site, and patient recruiting is expected to begin in Q3 2025.

To learn more about the SCLC trial and eligibility, please visit https://clinicaltrials.gov/study/NCT06922539

With compelling science, expanding clinical partnerships, and a next-generation drug delivery platform, SciTech is well-positioned to drive real impact for patients and value for stakeholders.

FUNDING UPDATE AND SERIES A LAUNCH

We are pleased to report that our investors have provided over $16 million in funding to date. This support has fueled key advancements in our T-cell NHL clinical trial and is paving the way for our upcoming Small Cell Lung Cancer (SCLC) trial, set to launch later this year.

Given our significant progress, we're excited to announce the launch of SciTech's $20 million Series A raise.

This raise will enable SciTech to complete the registrational trial for ST-001 nanoFenretinide and will support the FDA regulatory process. The company is anticipating targeting FDA filings within just 12 to 18 months—a rare and compelling timeline in oncology drug development. If you're interested in learning more about participating in our next phase of growth, reach out to David Schaffer, Investor Relations/Business Development at **drs@scitechdevelopment.com**

INVESTOR INSIGHT

Brad Daniels, CFA, an early investor in SciTech, shares his perspective on why he recognized the company's potential.

"I decided to invest in SciTech because they've addressed a long-standing challenge - making fenretinide a viable cancer treatment. Prior clinical research has shown that fenretinide could have a significant impact on a wide variety of cancers, but there was one issue that was tough to overcome… insolubility. Scientists have had a difficult time getting it to the cancer cells, but SciTech appears to have found the answer.

Their nanoparticle delivery platform has transformed this well-researched molecule with historically poor bioavailability into a high-dose therapy with strong IP protection. The fact that they've already seen partial responses with minimal negative side effects this early in the trial, gives me real confidence that SciTech is developing something with disruptive potential in oncology."

FINANCIAL MILESTONES

SciTech has made major strides this past year to position the company for long-term growth and success. We officially converted to a Delaware "C" Corporation, setting the stage to attract more institutional investment, streamline governance, and scale with confidence.

We've implemented Carta software for cap table management, compliance, and investor reporting, along with a comprehensive equity incentive plan, designed to attract and retain top-tier talent.

Our 2024 financial audit is nearly complete, and we're continuously enhancing our budgeting, forecasting, and financial planning systems.



SPOTLIGHT ON JOHN CHAPMAN, CPA: SENIOR FINANCIAL ADVISOR

We're proud to recognize John Chapman, CPA, as Senior Financial Advisor on our Strategic Advisory Board.

With decades of leadership in financial strategy and deep roots in the pharmaceutical industry, John brings a level of expertise that will be instrumental in guiding SciTech through our next phase of growth.

A former Senior Partner at KPMG, John held several top leadership roles, including serving on the Board of Directors for KPMG LLP and KPMG Americas. He also led the firm's Global Pharmaceuticals Practice, working closely with industry giants like Pfizer, Hoechst AG, and PepsiCo. John has advised executive teams and boards on everything from IPOs and M&A deals to SEC reporting and intangible asset valuation. He is also recognized as a Financial Expert by the SEC.

We're incredibly lucky to have John on board. Read The Press Release.

MANUFACTURING: SCALING UP FOR CLINICAL IMPACT

We'd like to share some great news regarding manufacturing - and it's a big step forward for SciTech.

Our manufacturing partner, The Plough Center for Sterile Drug Delivery Solutions, recently completed two large 48-liter batches of ST-001 nanoFenretinide, effectively doubling our production to keep pace with growing clinical demand. Once final release testing for the drug is wrapped up, these batches will head to our distribution partner, Sharp Clinical Services, and from there, straight to our clinical sites.

It's not just about having the capacity; it's about ensuring every patient in our trials gets safe, reliable, and timely access to treatment as we grow.

STRENGTHENING OUR IP AND COMPETITIVE EDGE

In January 2025, SciTech filed a new patent application for ST-001 nanoFenretinide. These advancements create a more formidable barrier to generic and non-generic fenretinide competition.

The new filing includes a range of important advancements:

- Newly defined mechanisms of action of the drug
- Broader potential disease indications beyond our current targets
- Optimized dosing strategies, including use in combination with other therapies
- Simplified treatment regimens designed to enhance patient access and compliance

We've built valuable proprietary know-how in ST-001 nanoFenretinide's formulation and manufacturing - protected as trade secrets to strengthen our defensibility.

Conferences & Events Recap

In recent months, the SciTech team has been actively sharing our mission, forging connections, and exploring strategic partnerships. Here's where we've been:

- JP Morgan Healthcare Conference – San Francisco, CA
- Boat Soirée – Miami, FL
- Clinical Trial Ventures Summit – Orlando, FL
- The Big Idea – Baltimore, MD
- BIO Investor Summit – New York, NY
- USCLC Annual Workshop – Orlando, FL
- MedInvest Biotech Conference – New York, NY
- Global Passions Project – Palm Beach, FL
- Moffitt Cancer Center Biotech Event – Tampa, FL
- Pointe Angels Portfolio Day – Detroit, MI
- ASCO Annual Meeting – May 30–June 4 | Chicago, IL

Where to Find Us Next

We're keeping the momentum going this summer with a strong lineup of conferences.

- BIO International Convention – June 16–19 | Boston, MA
- Opal Family Office Event – July 21–23 | Newport, RI
- 26th IASLC Intl. Lung Cancer Congress – July 25–26 | Huntington Beach, CA

Reach out to David Schaffer at drs@scitechdevelopment.com to schedule time with our team at any of these events.

Stay tuned to our social media for updates!

LOOKING AHEAD

It's an exciting time at SciTech!

With strong early clinical trial data, expanded manufacturing capacity, and IND approval to begin our trial in small cell lung cancer, we're in a great position to keep building on this progress.

Our focus remains clear: move ST-001 nanoFenretinide through the clinic with the goal of FDA approval.

The SciTech team is glad to have you with us!